SCHEMBL2528824

SCHEMBL2528824

FC(F)(F)c1ccn(C(F)(F)F)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.38
NPC1 O15118 4/20 0.35
RAB9A P51151 3/20 0.35
MAPT P10636 3/20 0.35
IDH1 O75874 4/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HTT P42858 1/20 0.33
PAX8 Q06710 1/20 0.33
IDH2 P48735 1/20 0.33
TRPV4 Q9HBA0 1/20 0.32
PTGS1 P23219 2/20 0.32
POLB P06746 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA3 P34903 1/20 0.31
LMNA P02545 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26846624 0.82
SCHEMBL951017 0.82 PRMT6 (0.39) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL2766709 0.82 PRMT6 (0.36) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL2764434 0.77 PRMT6 (0.36) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL28051010 0.76 ALDH1A1 (0.41) PRMT6NPC1RAB9AMAPTPTGS1
SCHEMBL21165939 0.73 IDH1 (0.39) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL27763596 0.73 LMNA (0.38) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL23421840 0.71 PRMT6 (0.38) PRMT6NPC1RAB9AMAPTIDH1
SCHEMBL20483217 0.71
SCHEMBL5139434 0.71 ALDH1A1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170202932-A1 METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2017-07-20 US claimed
US-20150190366-A1 METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2015-07-09 US claimed
WO-2014005186-A1 METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2014-01-09 WO claimed
US-20020091268-A1 Pyrazolate copper complexes, and MOCVD of copper using same XU CHONGYING (US) 2002-07-11 US claimed
WO-2001068948-A1 PYRAZOLATE COPPER COMPLEXES, AND MOCVD OF COPPER USING SAME ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2001-09-20 WO claimed
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome CALCIMEDICA, INC. (US) 2026-02-10 US disclosed
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS AVENUE CAPITAL MANAGEMENT II, L.P. 2025-04-17 US disclosed
EP-4465988-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS Calcimedica, Inc. (US) 2024-11-27 EP disclosed
WO-2023141523-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS CALCIMEDICA, INC. (US) 2023-07-27 WO disclosed
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME AVENUE CAPITAL MANAGEMENT II, L.P. 2023-04-20 US disclosed
EP-4121089-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME Calcimedica, Inc. (US) 2023-01-25 EP disclosed
WO-2021189013-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME CALCIMEDICA, INC. (US) 2021-09-23 WO disclosed
WO-2009095719-A2 TREATMENT OF MAST CELL RELATED DISORDERS ISIS INNOVATION LIMITED (GB) 2009-08-06 WO disclosed
US-20070267959-A1 Phosphorescent heteronuclear copper(I)-iridium(III) complex and organic electroluminescence device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2007-11-22 US disclosed
US-6639080-B2 Reacting bis(trifluoromethyl)pyrazole with a stoichiometric excess of copper oxide(Cu2O) and recovering bis(trifluoromethyl)pyrazolyl copper, or adding Lewis base ligand to form an adduct of above and Lewis base ADVANCED TECHNOLOGY MATERIALS, INC. 2003-10-28 US disclosed
US-6440202-B1 METALORGANIC CHEMICAL VAPOR DEPOSITION (MOCVD); REDUCED OXY CONTENT, OR OXYGEN-FREE; FOR LIQUID DELIVERY OF CVD COPPER; GOOD ADHESION AND ELECTROCONDUCTIVITY ADVANCED TECHNOLOGY MATERIALS, INC. 2002-08-27 US disclosed
US-20020091268-A1 Pyrazolate copper complexes, and MOCVD of copper using same XU CHONGYING (US) 2002-07-11 US disclosed
US-6417369-B1 LEWIS ACID ADDUCTS; SEMICONDUCTORS, INTEGRATED CIRCUITS; THIN FILM RECORDING HEAD ADVANCED TECHNOLOGY MATERIALS, INC. 2002-07-09 US disclosed
US-20020042518-A1 Pyrazolate copper complexes, and MOCVD of copper using same XU CHONGYING (US) 2002-04-11 US disclosed
WO-2001068948-A1 PYRAZOLATE COPPER COMPLEXES, AND MOCVD OF COPPER USING SAME ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070267959-A1 Phosphorescent heteronuclear copper(I)-iridium(III) complex and organic electroluminescence device using the same ORC3, AP3M1, PUF60 PRMT6 3930/4885NPC1 3670/4885RAB9A 1969/4885
US-20020042518-A1 Pyrazolate copper complexes, and MOCVD of copper using same SOD1, JUND, AOC1 PRMT6 3790/4885NPC1 4484/4885RAB9A 1419/4885
US-12544371-B2 Methods and compositions for treating acute lung injury and acute respiratory distress syndrome ORAI1, MAVS, CASR PRMT6 2352/4885NPC1 3859/4885RAB9A 586/4885
US-20020091268-A1 Pyrazolate copper complexes, and MOCVD of copper using same SOD1, JUND, AOC1 PRMT6 3790/4885NPC1 4484/4885RAB9A 1419/4885
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS IL1B, MAVS, MMP8 PRMT6 2577/4885NPC1 4241/4885RAB9A 1122/4885
US-20230120819-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME MAVS, ATF1, IL1B PRMT6 2645/4885NPC1 4239/4885RAB9A 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.